"Benzoquinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
Below are MeSH descriptors whose meaning is more general than "Benzoquinones".
Below are MeSH descriptors whose meaning is more specific than "Benzoquinones".
This graph shows the total number of publications written about "Benzoquinones" by people in this website by year, and whether "Benzoquinones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Benzoquinones" by people in Profiles.
Genetic and Biochemical Analysis of Anaerobic Respiration in Bacteroides fragilis and Its Importance In Vivo. mBio. 2020 02 04; 11(1).
The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model. Int J Mol Sci. 2020 Jan 17; 21(2).
A flavin-based extracellular electron transfer mechanism in diverse Gram-positive bacteria. Nature. 2018 10; 562(7725):140-144.
Molecular chaperone Hsp90 is a therapeutic target for noroviruses. J Virol. 2015 Jun; 89(12):6352-63.
The bacterial response regulator ArcA uses a diverse binding site architecture to regulate carbon oxidation globally. PLoS Genet. 2013; 9(10):e1003839.
Molecular mechanism of quinone signaling mediated through S-quinonization of a YodB family repressor QsrR. Proc Natl Acad Sci U S A. 2013 Mar 26; 110(13):5010-5.
NMR studies reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1. Biochemistry. 2011 Dec 06; 50(48):10540-9.
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011 Sep 13; 20(3):400-13.
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30.
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.